| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785732 | Cancer Treatment and Research Communications | 2018 | 6 Pages |
Abstract
Elevated serum bone biomarker levels are associated with worse OS in bone-metastatic CRPC. Bone biomarkers can identify unique prognostic subgroups. These results further define the role of bone biomarkers in the design of CRPC trials.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
P.N. Lara Jr., M. Plets, C. Tangen, E. Gertz, N.J. Vogelzang, M. Hussain, P.W. Twardowski, M.G. Garzotto, J.P. Monk, M. Carducci, A. Goldkorn, P.C. Mack, I. Thompson, M. Van Loan, D.I. Quinn,